Dianthus initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Dianthus with an Outperform rating and $48 price target The analyst cites the company having a “potential best-in-class opportunity” for lead candidate DNTH103 in multibillion-dollar rare autoimmune conditions including generalized myasthenia gravis, multifocal motor neuropathy , and chronic inflammatory demyelinating polyneuropathy. Outperform sees DNTH103 demonstrating potentially superior dosing/efficacy compared to on-market and late clinical-stage products in clinical trials, and anticipate data would support uptake in burgeoning markets across indications, led by the market expansion efforts of multiple pharma competitors, the firm tells investors in a research note.